How to use vancomycin optimally in neonates: remaining questions

References

• Cohen-Wolkowiez M, Moran C, Benjamin DK, et al. Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J 2009;28:1052e7
   Web of Science ®Google Scholar
• Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996;129:63e71
   Google Scholar
• Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002;347:240e7
   Web of Science ®Google Scholar
• Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med 2013;18:28-34
   PubMed Web of Science ®Google Scholar
• Revised priority list for studies into off-patent paediatric medicinal products (EMA/98717/2012). European Medicines Agency, London, UK. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004017.pdf
   Google Scholar
• Dawson PM. Vancomycin and gentamicin in neonates: hindsight, current controversies, and forethought. J Perinat Neonatal Nurs 2002;16:54-72
   PubMed Web of Science ®Google Scholar
• Rubin LG, Sánchez PJ, Siegel J, et al. Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late-onset sepsis: a survey of neonatologists’ practices. Pediatrics 2002;110:e42
   PubMed Web of Science ®Google Scholar
• Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 1993;37:1132-6
   PubMed Web of Science ®Google Scholar
• Lundstrom TS, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin. Infect Dis Clin North Am 2004;18:651-68
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Albrecht LM, Berman JR, et al. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990;34:792-5
   PubMed Web of Science ®Google Scholar
• Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and non renal clearances in normal human subjects. Clin Pharmacol Ther 1988;43:565-70
   PubMed Web of Science ®Google Scholar
• de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 2004;43:417-40
   PubMed Web of Science ®Google Scholar
• Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet 2012;51:1-13
   PubMed Web of Science ®Google Scholar
• Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007;46:221-34
   PubMed Web of Science ®Google Scholar
• Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit 2007;29:284-91
   PubMed Web of Science ®Google Scholar
• Kimura T, Sunakawa K, Matsuura N, et al. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 2004;48:1159-67
   PubMed Web of Science ®Google Scholar
• Lo YL, van Hasselt JG, Heng SC, et al. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother 2010;54:2626-32
   PubMed Web of Science ®Google Scholar
• Marqués-Miñana MR, Saadeddin A, Peris JE. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol 2010;70:713-20
   PubMed Web of Science ®Google Scholar
• Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed 1999;81:F221-7
   PubMed Web of Science ®Google Scholar
• Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001;41:927-34
   PubMed Web of Science ®Google Scholar
• Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol 2013;75(4):1068-80
   PubMed Web of Science ®Google Scholar
• Leroux S, Zhao W, Bétrémieux P, et al. Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. ADC 2015;10.1136/archdischild-2014-306873
   Google Scholar
• van den Anker JN. Renal function in preterm infants. Eur J Pediatr 1997;156:583-4
   PubMed Web of Science ®Google Scholar
• Peake M, Whiting M. Measurement of serum creatinine–current status and future goals. Clin Biochem Rev 2006;27:173-84
   PubMedGoogle Scholar
• Anne L, Hu M, Chan K, et al. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit 1989;11:585-91
   PubMed Web of Science ®Google Scholar
• Smith PF, Morse GD. Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease. Ann Pharmacother 1999;33:1329-35
   PubMed Web of Science ®Google Scholar
• Legatt DF, Blakney GB, Higgins TN, et al. The effect of paraproteins and rheumatoid factor on four commercial immunoassays for vancomycin: implications for laboratorians and other health care professionals. Ther Drug Monit 2012;34:306-11
   PubMed Web of Science ®Google Scholar
• Zhao W, Jacqz-Aigrain E. The importance of knowing how vancomycin is measured when interpreting its pharmacokinetic results. Ther Drug Monit 2013;35:416
   PubMed Web of Science ®Google Scholar
• EMA. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 1). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf
   Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphyloccocus Aureus lower respiratory tract infection. Clin Pharmacokinet 2004;43:925-42
   PubMed Web of Science ®Google Scholar
• Rubak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults: summary of consessus from the american society of health-ssystem pharmacists, the infectiuos diseases society of america and the society of infectious diseases pharmacists. Pharmacotherapy 2009;28:1275-9
   Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43(13):925-42
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the american society of health-system pharmacists, the infectious diseases society of america, and the society of infectious diseases pharmacists. Pharmacotherapy 2009;29:1275-9
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402
   PubMed Web of Science ®Google Scholar
• EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance – Version 1.0 - October 2013. Available from: www.eucast.org January 2015
   Google Scholar
• Ho PL, Lo PY, Chow KH, et al. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J Infect 2010;60:140-5
   PubMed Web of Science ®Google Scholar
• Moise P, Sakoulas G, Forrest A, et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteraemia. Antimicrob Agents Chemother 2007;51:2582-6
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez J, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteraemia. Clin Infect Dis 2008;46:193-200
   Google Scholar
• The antimicrobial KnowledgeBase. Available from: www.antibiotics.toku-e.com
   Google Scholar
• Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007;44:1536-42
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Hersh AL, Coralic Z, et al. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther 2010;32:534-42
   PubMed Web of Science ®Google Scholar
• Klingenberg C, Aarag E, Rønnestad A, et al. Coagulase-negative staphylococcal sepsis in neonates. Association between antibiotic resistance, biofilm formation and the host inflammatory response. Pediatr Infect Dis J 2005;24:817-22
   PubMed Web of Science ®Google Scholar
• Marchant EA, Boyce GK, Sadarangani M, Lavoie PM. Neoatal sepsis due to coagulase-negative staphylococci. Clin Dev Immunol 2013;2013:586076
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol 2010;11:373-84
   PubMed Web of Science ®Google Scholar
• Baquero F, Coque TM, Cantón R. Counteracting antibiotic resistance: breaking barriers among antibacterial strategies. Expert Opin Ther Targets 2014;18:851-61
   PubMed Web of Science ®Google Scholar
• Canton R, Morosini M. Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev 2011;35:977-91
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gentry CA, Plank GS, et al. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995;17:239-46
   PubMed Web of Science ®Google Scholar
• Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012;68:1243-55
   PubMed Web of Science ®Google Scholar
• Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1988;3:376-86
   PubMedGoogle Scholar
• McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011;158:422-6
   PubMed Web of Science ®Google Scholar
• Odio C, McCracken GHJr, Nelson JD. Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children. J Pediatr 1984;105:491-3
   PubMed Web of Science ®Google Scholar
• Goren MP, Baker DKJr, Shenep JL. Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 1989;8:278-82
   PubMed Web of Science ®Google Scholar
• Linder N, Edwards R, MeClead R, et al. Safety of vancomycin with or without gentamicin in neonates. Neonatal Netw 1993;12:27-30
   PubMedGoogle Scholar
• Schreuder MF, Bueters RR, Allegaert K. The interplay between drugs and the kidney in premature neonates. Pediatr Nephrol 2014;29:2083-91
   PubMed Web of Science ®Google Scholar
• Schaad UB, Nelson JD, McCracken GHJr. Pharmacology and efficacy of vancomycin for staphylococcal infections in children. Rev Infect Dis 1981;3:S282-8
   PubMedGoogle Scholar
• Burkhart KK, Metcalf S, Shurnas E, et al. Exchange transfusion and multidose activated charcoal following vancomycin overdose. J Toxicol Clin Toxicol 1992;30:285-94
   PubMed Web of Science ®Google Scholar
• de Hoog M, van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003;142:41-6
   PubMed Web of Science ®Google Scholar
• Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections:prospective multicenter randomized study. Antimicrob Agents Chemother 2009;53:1863-7
   PubMed Web of Science ®Google Scholar
• Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2001;45:2460-7
   PubMed Web of Science ®Google Scholar
• Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012;67:17-24
   PubMed Web of Science ®Google Scholar
• Plan O, Cambonie G, Barbotte E, et al. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule. Arch Dis Child Fetal Neonatal Ed 2008;93:F418-21
   PubMed Web of Science ®Google Scholar
• Pawllotsky F, Thomas A, Kergueris MF, et al. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol 1998;46:163-7
   PubMed Web of Science ®Google Scholar
• Oudin C, Vialet R, Boulamery A, et al. Vancomycin prescription in neonates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed 2011;96:F365-70
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov: A service of the U.S National Institute oh Health. Available from: https://clinicaltrials.gov
   Google Scholar
• Gwee A, Cranswick N, Metz D, et al. Neonatal vancomycin continuous infusions: still a confusion? Pediatr Infect Dis J 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Ward RM, Allegaert K, de Groot R, van den Anker JN. Commentary: Continuous infusion of vancomycin in neonates: to use or not to use remains the question. Pediatr Infect Dis J 2014;33:606-7
   PubMed Web of Science ®Google Scholar
• Sherwin CM, Medlicott NJ, Reith DM, Broadbent RS. Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child 2014;99:590-4
   PubMed Web of Science ®Google Scholar
• Isaacs D, Wilkinson AR, Moxon ER. Duration of antibiotic courses for neonates. Arch Dis Child 1987;62:727-8
   PubMed Web of Science ®Google Scholar
• Bizzaro JM, Gallagher PG. Antibiotic resistant organisms in the neonatal intensive care unit. Seminars Perinatol 2007;31:26-32
   PubMed Web of Science ®Google Scholar
• Stronati M, Borghesi A, Decembrino L, Bollani L. Antibiotics in neonatal intensive care units (NICUs). J Chemother 2007;19:52-5
   PubMedGoogle Scholar
• Aguado-Lorenzo V, Weeks K, Tunstell P, et al. Accuracy of the concentration of morphin infusions prepared for patients in a NICU. Arch Dis Child 2013;98:975-9
   PubMed Web of Science ®Google Scholar
• WHO. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for a drug regulatory authority. World Health Organization, Geneva, Switzerland. Available from: http://apps.who.int/prequal/info_general/documents/WHO_DMP_RGS_98_5_R.pdf
   Google Scholar
• Jong GW. In vivo inferiority of generic product compared with branded vancomycin: a paradigm shift. Ther Drug Monit 2012;34:2-3
   PubMed Web of Science ®Google Scholar
• Louie A, Boyne MT, Patel W, et al. Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States. AAC 2015;59:622-32
   Web of Science ®Google Scholar
• Raverdy V, Ampe E, Hecq JD, Tulkens PMJ. Stability and compatibility of vancomycin for administration by continuous infusion. Antimicrob Chemother 2013;68:1179-82
   Web of Science ®Google Scholar
• Berti AD, Hutson PR, Schulz LT, et al. Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion. Am J Health Syst Pharm 2015;72:390-5
   PubMed Web of Science ®Google Scholar
• Pritts D, Hancock D. Incompatibility of ceftriaxone with vancomycin. Am J Hosp Pharm 1991;48:77
   PubMedGoogle Scholar
• The IV compatibility table IV. Available from: www.nursingconsult.com
   Google Scholar
• Ringenberg T, Robinson C, Meyers R. Achievement of therapeutic vancomycin trough serum concentration with empirical dosing in neonatal intensive care unit patients. Pediatr Infect Dis J 2015; Epub anead of print
   PubMedGoogle Scholar
• Patel MP, Pai KA, Rodvold B, et al. Vancomycin: we can’t get there from here. Clin Infect Dis 2011;52:969-74
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Hersh AL, El-Komy MH, et al. Association between vancomycin trough concentrations and area under the concentration-time curve inneonates. Antimicrob Agents Chemother 2014;58:6454-61
   PubMed Web of Science ®Google Scholar
• Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev 2014;20:50-7
   Web of Science ®Google Scholar
• Gross JR, Kaplan SL, Kramer WG, Mason EOJr. Vancomycin pharmacokinetics in premature infants. Pediatr Pharmacol (New York) 1985;5:17-22
   PubMedGoogle Scholar
• Naqvi SH, Keenan WJ, Reichley RM, Fortune KP. Vancomycin pharmacokinetics in small, seriously ill infants. Am J Dis Child 1986;140:107-10
   PubMedGoogle Scholar
• Spivey JM, Gal P. Vancomycin pharmacokinetics in neonates. Am J Dis Child 1986;140:859
   PubMedGoogle Scholar
• James A, Koren G, Milliken J, et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987;31:52-4
   PubMed Web of Science ®Google Scholar
• Reed MD, Kliegman RM, Weiner JS, et al. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res 1987;22:360-3
   PubMed Web of Science ®Google Scholar
• Lisby-Sutch SM, Nahata MC. Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988;35:637-42
   PubMed Web of Science ®Google Scholar
• Kildoo CW, Lin LM, Gabriel MH, et al. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 1989;14:77-83
   PubMedGoogle Scholar
• Leonard MB, Koren G, Stevenson DK, Prober CG. Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J 1989;8:282-6
   PubMed Web of Science ®Google Scholar
• Jarrett RV, Marinkovich GA, Gayle EL, Bass JW. Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants. Pediatr Infect Dis J 1993;12:156-7
   PubMed Web of Science ®Google Scholar
• Asbury WH, Darsey EH, Rose WB, et al. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation. Ann Pharmacother 1993;27:490-6
   PubMed Web of Science ®Google Scholar
• McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995;17:319-26
   PubMed Web of Science ®Google Scholar
• Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996;40:1139-42
   PubMed Web of Science ®Google Scholar
• Burstein AH, Gal P, Forrest A. Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. Ann Pharmacother 1997;31:980-3
   PubMed Web of Science ®Google Scholar
• Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1998;18:1082-6
   PubMed Web of Science ®Google Scholar
• Fofah OO, Karmen A, Piscitelli J, Brion LP. Failure of prediction of peak serum vancomycin concentrations from trough values in neonates. Pediatr Infect Dis J 1999;18:299-301
   PubMed Web of Science ®Google Scholar
• Frattarelli DA, Ergun H, Lulic-Botica M, et al. Vancomycin elimination in human infants with intrauterine growth retardation. Pediatr Infect Dis J 2005;24:979-83
   PubMed Web of Science ®Google Scholar
• Machado JK, Feferbaum R, Kobayashi CE, et al. Vancomycin pharmacokinetics in preterm infants. Clinics (Sao Paulo) 2007;62:405-10
   PubMed Web of Science ®Google Scholar
• Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther 1994;56:169-75
   PubMed Web of Science ®Google Scholar
• de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther 2000;67:360-7
   PubMed Web of Science ®Google Scholar
• Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005;60:265-75
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007;63:75-84
   PubMed Web of Science ®Google Scholar
• Mehrotra N, Tang L, Phelps SJ, Meibohm B. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy 2012;32:408-19
   PubMed Web of Science ®Google Scholar
• Zhao W, Lopez E, Biran V, et al. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child 2013;98:449-53
   PubMed Web of Science ®Google Scholar
• Patel AD, Anand D, Lucas C, Thomson AH. Continuous infusion of vancomycin in neonates – PostScript/letters. Arch Dis Child 2013;98:478-9
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Allegeart K. Clinical pharmacokinetics of vancomycin in the neonate: a review. Clinics 2012;67:831-7
   PubMed Web of Science ®Google Scholar